Studies Confirm Effectiveness of Stereotactic Neurosurgery
By Medimaging International staff writers
Posted on 02 May 2017
Image: The Leksell Gamma Knife Icon, a minimally invasive stereotactic neurosurgery system (Photo courtesy of Elekta).
New studies have confirmed the clinical effectiveness of a minimally invasive stereotactic neurosurgery system used to treat brain cancer, other non-cancerous brain tumors, and neurological conditions in patients.
The medical imaging systems provider also showcased a new stereotactic neurosurgery system intended for target localization, and coordinate referencing in precision neurosurgery.
The Leksell Gamma Knife developed by Elekta was featured in more than 15 scientific presentations at the annual meeting of the American Association of Neurological Surgeons (AANS) in Los Angeles, California, in the US, in April 2017. The head frame of the new Leksell Vantage Stereotactic system is made from a novel epoxy composite material designed to improve the speed, imaging quality, and patient comfort during neurosurgery procedures.
The new Leksell Vantage system is pending 510(k) clearance by US Food and Drug Administration, but received CE (Conformité Européenne) Mark clearance in March 2017, and will now be put into clinical practice in Europe for the first time in hospitals in France, the Netherlands, the UK, and Sweden.
VP of the Neuroscience portfolio at Elekta, Jesper Söderqvist, said, "Our Leksell Stereotactic System has been helping clinicians achieve outstanding patient outcomes for more than 60 years, and Vantage improves upon this gold standard platform to deliver uncompromising accuracy in stereotactic imaging and treatment. With potential for faster imaging, more efficient workflow, reduced artifacts and a better overall user experience, Leksell Vantage is a welcome advancement for physicians and their patients."